Dr. Lewis holds the Bird Dogs Chair in Translational Oncology at the University of Alberta and is a Professor in the Department of Oncology. Dr. John Lewis’s research interests lie in the areas of nanotechnology and imaging as they relate to oncology, infectious diseases and age-related disease. His group is focused mainly on the study of the spread, or metastasis, of cancer using advanced live imaging techniques.
Dr. Lewis is an active entrepreneur, and has founded several biotechnology companies including Entos Pharmaceuticals, Nanostics, OncoSenX and Aegis Life.
Entos Pharmaceuticals is an Edmonton-based biotechnology company developing genetic medicines using the Fusogenix drug delivery system. Entos has developed a COVID-19 vaccine in Phase 2 clinical trials. Aegis Life was launched in 2020 to develop vaccines and treatments for infectious disease using the Fusogenix platform.
Nanostics is an Edmonton-based healthcare biotechnology company focused on development and commercialization of novel, non-invasive diagnostic tests. Their lead product, ClarityDX Prostate, is an accurate blood test to diagnose aggressive prostate cancer.

OncoSenX is a late stage pre-clinical cancer company with a next generation cancer gene therapy. This approach is a more precise intervention for this complex and devastating disease.